AzTrials
AzTrials

Critical Care, Intensive CareNMESNCT06897774

Does Transcutaneous Phrenic Nerve Stimulation Prevent Diaphragm Atrophy?

An observational study of Critical Care, Intensive Care, run by Bakirkoy Dr. Sadi Konuk Research and Training Hospital at 1 site in Turkey (Türkiye).

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Dear participant Participants's patient, who is participants's first-degree relative, who is connected to a ventilator in the intensive care unit, unconscious and not authorized to give informed consent, has been invited to participate in the study titled 'Does transcutaneous phrenic nerve stimulation prevent… Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Critical Care, Intensive Care
How many people
80 participants
Where
1 siteTurkey (Türkiye)
Study dates
22 Jan 2024to 22 Apr 2025
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients on invasive mechanical ventilation for 72 hours or more Patients older than 18 years

Who may be able to join

None listed.

Who cannot join

  • Patients with less than 72 hours of mechanical ventilation
  • Pregnancy
  • Patients with a body mass index above 35kg/m²
  • Neuromuscular disease
  • Refractory epilepsy
  • Patients with pacemakers
Show all 12Show fewer
  • ARDS
  • Unilateral or bilateral diaphragm paralysis
  • Presence of pneumothorax
  • Patients with large right pleural effusion
  • Tracheostomized patients
  • Patients undergoing upper abdominal surgery

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Turkey (Türkiye)1 site, 1 recruiting
  • Dr.SadiKonuk EAH

    Istanbul, Bakirkoy

    DrSadiKonuk DrSadiKonuk, +9 ext. 0212 3777138

    Safiye Tuba Kaplan

    Recruiting

Other trials in Turkey (Türkiye)

About this study

Dear participant Participants's patient, who is participants's first-degree relative, who is connected to a ventilator in the intensive care unit, unconscious and not authorized to give informed consent, has been invited to participate in the study titled 'Does transcutaneous phrenic nerve stimulation prevent diaphragm atrophy?

In order to strengthen this muscle and prevent loss of function, investigator provide electrical stimulation between the rib cage and abdomen through the skin with the tens device, causing the muscle to contract and enabling our patient to leave the respirator early.

Read more

Investigator aimed to investigate the protective effect of the tens device on the diaphragm by evaluating the diaphragm muscle with the ultrasonography device during the period when it is connected to the respirator. For this reason, the diaphragm will be contracted by giving electrical stimulation three times a day for 30 minutes with the tens device for 5 days during the period when participants's patient is connected to the respirator, and intermittent diaphragm ultrasound will be evaluated.

Participants or participants's legal guardian are asked to approve the use of participants's medical records during participants's treatment in the intensive care unit, provided that participants's personal information is kept confidential. Participants will not incur any financial burden by participating in the study and participants will not receive any additional payment.

Participants are free to leave the study at any time if deemed necessary, and the researcher can terminate the study if deemed necessary. The information obtained within the scope of the research can be used for scientific purposes and can be presented and published provided that the confidentiality record is respected.

I have read (or orally listened to) the text above, which contains the information given to the participants before the research began. I agree to participate in the study as a Volunteer. I consent to the use of my medical information. I also understand that if I do not agree to participate in the study, my treatment will be carried out in full without interruption.

Participant name and surname:

Participant's relative's name and surname:

Degree of closeness:

Signature / Date:

Read the detailed description

In our study, investigator will investigate the effects of early and late trancutaneous phrenic nerve cytimulation on the prevention of diaphragm atrophy in invasive mechanical ventilation patients (>72 hours MV requirement).

Material and Methods of the Study Our study was planned as prospective, single-center, observational. As a result of the power analysis investigator performed for our study, the minimum sample size was calculated as 40 people for each group and 80 people in total with a 90% confidence interval.

Our study will be conducted as specified in the 1995 Declaration of Helsinki

The patients admitted to the Intensive Care Unit of the Anesthesia and Reanimation Clinic of the University of Health Sciences Bakırköy Dr. Sadi Konuk Training and Research Hospital Anesthesia and Reanimation Clinic Intensive Care Unit between February 1, 2024 and February 1, 2025, the effects of early and late transcutaneous phrenic nerve cytimulation on the diaphragm, diaphragmatic ultrasound and the patient's data registered in the Metavision /QlinICU Clinical Decision Support Software System will be obtained by Structured Query Language (SQL) queries. Vital parameters, hemodynamic, ventilator parameters, laboratory and demographic data will be extracted from the data pool.

Demographic data, biochemical parameters, comorbidities, indications for intubation, duration of invasive mechanical ventilation, respiratory rate, saturation, tidal volume, compliance, FiO2, Peep, above Peep, weaning criteria, peak heart rate, systolic \& diastolic blood pressure, Mean arterial pressure, nutritional assessment, balance status, sedation status, length of ICU and hospital stay, and SOFA, APACHI II, Charlson comorbidity Index (CCI) and Ramsey sedation scores will be extracted from the electronic data system to homogenize the groups.

Patients will be divided into two groups according to early and late transcutaneous electrical diaphragmatic stimulation (TEDS). Group 1 patients with early TEDS will start TEDS at T1 and continue for 5 days. Group 2 patients receiving late TEDS will start TEDS at T2 and continue for 5 days.

Patients receiving invasive mechanical ventilation will receive transcutaneous electrical diaphragmatic stimulation (TEDS) for 30 minutes at 8-hour intervals for 5 days, starting immediately after intubation (0.hour) and 48 hours later. During each session, round electrodes will be placed in the parasternal region, near the xiphoid process, and in the sixth and seventh intercostal spaces in line with the mid-axillary line. TEDS will be performed using a commercial stimulator (Longest MStim Reha LGT_231 portable Electro-Stimulation Therapy Device/China) that applies electrical waves with a frequency of 60Hz, a pulse width of 300 μs and a strength of 30 milliamps. Each stimulation will be applied for 30 seconds: 5 seconds rise time, 5 seconds stimulation time, 5 seconds descent time, 15 seconds listening time. Each session will last 30 minutes and will be performed three times a day. 60 stimulations per session and 180 stimulations per day will be applied to the patient. Stimulation will not be applied when patients are under curare, in pron position, hemodynamically unstable despite catecholamines and agitated (Ramsay sedation score 1/6). The cycles would not be fully synchronized with inspiration as the patients would be ventilated in controlled and pressure support modes.

Patients will undergo diaphragm evaluation with ultrasonography at certain time intervals.

T1: intubation +4h T2: 48.hour+ 4h T3: day 5+4h US-guided diaphragm measurements will be performed in the semi-recumbent position. For evaluation of diaphragm thickness parameters, the diaphragm will be visualized by placing the 7 MHz transducer in the apposition zone perpendicular to the chest wall, in the eighth or ninth intercostal space, between the anterior axillary and midaxillary lines. The diaphragm will be visualized as a structure consisting of two echoic lines (diaphragmatic pleura and peritoneal membrane) and a hypoechoic structure between them (the muscle itself). During quiet tidal breathing, several images of the diaphragm will be taken, at least three at the point of inspiration and at least three at the end of expiration. In each B-mode image, the diaphragm thickness (Tdi) will be measured from the center of the pleural line to the center of the peritoneal line. These three measurements will be averaged and then the diaphragm thickness fraction (DTF) will be calculated as a percentage using the following formula: (End-inspiratory thickness - End-expiratory thickness)/ End-expiratory thickness. To assess the movement of the diaphragm, the 3.5 MHz probe will be placed in the mid-clavicular line below the right subcostal border and moved until the posterior third of the right diaphragm is better visualized. During tidal breathing, M-mode will be used to visualize diaphragm movement along a selected line perpendicular to the diaphragm.

Transcutaneous electrical diaphragm stimulation for both groups will be used in our daily practice.

Patients will be scheduled at the frequency and in the way of application that investigators routinely apply and the routine will not be deviated from.

Statistical Method

GraphPad Prism (v 5.01) program will be used for statistical analysis of the findings obtained in the study. Homogeneity of the variables will be determined by Shapiro-Wilk normality test. Pairwise comparisons of the groups' parameters and demographic data will be compared by Mann Whitney U test, and median and interquartile range (IQR) values will be used in statistical representation. Frequency distribution and percentage values of categorical variables such as gender and intensive care mortality will be compared with the Chi-square test. Within-group repeated measures will be compared by Wilcoxon test for pairwise comparisons and repeated MANOVA for multiple comparisons of more than two parameters. Benforini tests will be used to determine whether there is a statistical difference between the variances. For the statistical representation of the Repeated MANOVA method results, the difference between means and the standard deviation values of the differences will be used. Among the statistical values, p < 0.05 will be considered significant. In the power analysis performed to determine the sample size, the number of patients required to be in each group for the power of the study to be above 80% was calculated as 40. Thus, the number of patients to be included in the study for both groups was calculated as 80.

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06897774
Study groupRoleWhat they receive
Early GroupThe group in which transcutaneous electrical nerve stimulation will be inserted immediately after intubation
Late GroupThe group to be fitted with transcutaneous electrical nerve stimulation 48 hours after intubation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Primary Outcome: Diaphragm atrophy, ventilator-associated diaphragm dysfunction

    By performing phrenic nerve stimulation with TEDS device, the thickness change in the diaphragm muscle will be measured by usg at the end of 5 days.

    The thickness of the diaphragm muscle will be measured in inspiratory and expiratory. Atrophy will be determined according to the change in thickness. Diaphragm thickening fraction will be calculated by formilizing the thickness in inspiratory and expiratory and diaphragm dysfunction will be determined.DTF (End-inspiratory thickness - End-expiratory thickness)/ End-expiratory thickness)x100. The following values will be accepted for the results.

    Diaphragmatic Atrophy:

    Diaphragm thickness<1-1.5cm Diaphragmatic thickness decreased by 10% compared to baseline

    Diaphragmatic Dysfunction:

    Diaphragmatic Thickening Fraction <20

    Measured: January 22 2024-April 22 2025

Secondary outcomes (1)
  1. 1.Duration of Mechanical Ventilation 2.Length of Stay in Intensive Care Unit

    1. Definition: Total duration of mechanical ventilation received by the patient. Unit of Measure: Hours
    2. Definition: Total length of stay in the intensive care unit. Unit of Measure: Days

    Measured: January 22 2024-April 22 2025

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Mar 2025
  2. Study start22 Jan 2024
  3. Primary completion22 Apr 2025 (estimated)
  4. Study completion22 Apr 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06897774
Sponsor's protocol ID
z2g6egpa
Acronym
NMES
Status last verified
Mar 2025
First submitted
6 Mar 2025
Last updated
27 Mar 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: I haven't decided yet

Questions about this trial

What is this clinical trial studying?

An observational study of Critical Care, Intensive Care, run by Bakirkoy Dr. Sadi Konuk Research and Training Hospital at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 0 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 27 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Safiye Tuba Kaplan (+9 ext. 05325690108, sipahituba79@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Primary Outcome: Diaphragm atrophy, ventilator-associated diaphragm dysfunction (time frame: January 22 2024-April 22 2025). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in